# Talus Bio **Source:** https://geo.sig.ai/brands/talus-bio **Vertical:** Healthcare **Subcategory:** General **Tier:** Emerging **Website:** talus.bio **Last Updated:** 2026-04-14 ## Summary Seattle AI drug discovery targeting transcription factors with MARMOT platform measuring 10,000 regulomes monthly; YC W21 $11.2M with FDA/EMA Phase I approval for MSD-001 cancer program. ## Company Overview Talus Bioscience is a Seattle-based AI-powered drug discovery company targeting transcription factors — the class of proteins historically considered "undruggable" that regulate gene expression and drive many cancers — using its proprietary MARMOT platform (MAssive Regulome Mapping Of Transcriptomes) to measure the binding activity of small molecules across 10,000+ regulomes monthly using live, unmodified human cells. Founded and backed by Y Combinator (W21) with $11.2 million in Seed+ funding raised in August 2024, Talus received FDA and EMA approval for Phase I human trials of its lead program MSD-001 in 2024 — advancing toward first-in-human studies for a transcription factor-targeted cancer therapy. Talus' MARMOT platform addresses the fundamental challenge of targeting transcription factors: while transcription factors are implicated in 50%+ of human cancers, their protein surfaces lack the deep pockets that small molecule drugs typically bind to, making them resistant to conventional drug discovery approaches. MARMOT measures how potential drug molecules change the binding patterns of transcription factors across thousands of gene regulatory elements simultaneously — using native human cell systems rather than artificial model organisms — generating a functional readout of whether a molecule disrupts transcription factor activity in a biologically relevant context. This high-throughput functional screening approach identifies transcription factor-targeting compounds that would be missed by structure-based drug design. In 2025, Talus Bioscience competes in the targeted cancer therapy and AI drug discovery market with Black Diamond Therapeutics (NASDAQ: BDTX, cancer mutations), Blueprint Medicines (NASDAQ: BPMC, precision oncology), and AI drug discovery platforms (Recursion Pharmaceuticals, NASDAQ: RXRX) for transcription factor-targeted cancer program development. FDA and EMA Phase I approval for MSD-001 de-risks the most significant regulatory milestone for first-in-class transcription factor inhibitors and validates the MARMOT platform's output. Y Combinator's backing places Talus in the intersection of biotech and computational biology communities. The 2025 strategy focuses on advancing MSD-001 through Phase I safety trials, generating proof-of-concept data that enables partnership or out-licensing with larger pharmaceutical companies for Phase II/III development, and using MARMOT's platform capabilities for additional transcription factor targets. ## Frequently Asked Questions ### What is Talus Bio? Talus Bioscience is a Seattle-based drug discovery company founded in 2019 that develops AI-powered therapeutics targeting transcription factors and the DNA regulome. The company focuses on previously undruggable cancer targets using its proprietary MARMOT platform technology. ### What products and services does Talus Bio offer? Talus Bio offers the MARMOT AI platform for drug discovery, transcription factor therapeutics, DNA regulome profiling, and cancer drug discovery services. The company also provides the Regulome Early Access Program and has developed Brachyury cancer programs including their lead program MSD-001. ### Who are Talus Bio's target customers? Talus Bio serves pharmaceutical companies and research institutions seeking novel therapeutic approaches to difficult-to-treat cancers. Their focus includes developing treatments for chordoma, non-small cell lung cancer, and advanced prostate cancer. ### When was Talus Bio founded? Talus Bio was founded in 2019 and participated in Y Combinator's Winter 2021 (W21) cohort. ### Where is Talus Bio located? Talus Bio is based in Seattle, Washington. ### What funding has Talus Bio raised? Talus Bio raised $11.2M in Seed+ funding in August 2024, led by Two Bear Capital. Additional investors include WRF Capital, NFX, YC Continuity Fund, Funders Club VC, and BoxOne Ventures. ### What are Talus Bio's key achievements? Talus Bio achieved FDA and EMA approval for Phase I human trials of their lead program MSD-001 in 2024 and can measure over 10,000 regulomes per month using live unmodified human cells. The company also presented preclinical data at the 2025 AACR Annual Meeting. ### What technology does Talus Bio use? Talus Bio uses its proprietary MARMOT platform technology, which combines AI-powered drug discovery with DNA regulome profiling. This technology enables the company to target previously undruggable transcription factors in cancer using live unmodified human cells. ### How can organizations access Talus Bio's services? Organizations can access Talus Bio's services through the Regulome Early Access Program, which launched in July 2025. ### What are the latest developments at Talus Bio? Recent developments include raising $11.2M in Seed+ funding in August 2024, receiving FDA and EMA approval for Phase I trials of MSD-001, and launching the Regulome Early Access Program in July 2025. The company also presented preclinical data on chordoma, non-small cell lung cancer, and advanced prostate cancer programs at the 2025 AACR Annual Meeting. ## Tags healthtech, saas, north-america, b2b --- *Data from geo.sig.ai Brand Intelligence Database. Updated 2026-04-14.*